Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Asset disposition
Quarterly results
Appointed director
CC transcript
MYLAN INC. (MYL) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/06/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
09/29/2021 EFFECT Form EFFECT - Notice of Effectiveness:
09/28/2021 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/10/2021 S-4 Form S-4 - Registration of securities, business combinations:
12/12/2018 EFFECT Form EFFECT - Notice of Effectiveness:
12/11/2018 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/09/2018 S-4 Form S-4 - Registration of securities, business combinations:
01/03/2017 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
01/03/2017 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
12/22/2016 S-4/A Form S-4/A - Registration of securities, business combinations [Amend]
12/01/2016 S-4 Form S-4 - Registration of securities, business combinations
04/30/2015 10-K/A Annual Report for the period ended December 31, 2014 [amend]
03/02/2015 10-K Annual Report for the period ended December 31, 2014
03/02/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Mylan Fourth Quarter 2014 Adjusted Diluted EPS Increases 35% to $1.05 and Full Year Adjusted Diluted EPS Up 23% to $3.56"
02/27/2015 8-K Form 8-K - Current report
02/12/2015 SC 13G WELLINGTON MANAGEMENT GROUP LLP reports a 5.1% stake in Mylan Inc.
02/11/2015 SC 13G/A VANGUARD GROUP INC reports a 7.7% stake in Mylan Inc/PA
01/30/2015 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
01/29/2015 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business PITTSBURGH - Jan. 29, 2015 - Mylan Inc. announced that at a Special Meeting of Shareholders held Jan. 29, 2015, Mylan's shareholders overwhelmingly approved the agreement implementing Mylan's pending acquisition of Abbott's non-U.S. developed markets specialty and branded generics business and reorganization in the Netherlands in an all-stock transaction. The agreement implementing the transaction received the approval of approximately 98% of the votes cast and the advisory vote on the proposal regarding certain compensation matters related to the transaction received the approval of approximately 82% of the votes cast. As previously an..."
01/28/2015 8-K Other Events
01/15/2015 SC 13G/A BlackRock Inc. reports a 9.3% stake in MYLAN INC
01/14/2015 8-K Investor presentation
Docs: "J.P. Morgan Healthcare Conference Transcript"
12/29/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
12/24/2014 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
11/05/2014 10-Q Quarterly Report for the period ended September 30, 2014
11/05/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/30/2014 8-K Quarterly results
Docs: "Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16 2014 Adjusted Diluted EPS Guidance Range Increases to $3.54 to $3.60"
10/22/2014 8-K Entry into a Material Definitive Agreement
10/16/2014 8-K Other Events
10/03/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range"
08/07/2014 10-Q Quarterly Report for the period ended June 30, 2014
08/07/2014 8-K Quarterly results
Docs: "Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance Narrows 2014 Adjusted Diluted EPS Guidance Range to $3.25 to $3.45"
08/06/2014 8-K Other Events, Financial Statements and Exhibits Interactive Data
Docs: "Consent of Deloitte & Touche LLP",
"Part II, Item 6. Selected Financial Data; Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; and Item 8. Financial Statements and Supplementary Data from the 2013 Annual Report, each as revised",
"Part IV, Item 15. Exhibits, Consolidated Financial Statement Schedules, 2. Consolidated Financial Statement Schedules: Schedule II - Valuation and Qualifying Accounts, as revised"
08/01/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy